We have experienced a paradigm shift in the treatment of diabetic retinopathy from laser to anti-VEGF therapy. Read along as we discuss the evidence from the latest clinical trials on how we can improve diabetic retinopathy. This patient experienced a 2 step improvement in DR severity after anti-VEGF treatment for 3 months.
Direct Link / Take the CME: Healio
|Author(s)/Faculty: Rishi P. Singh, MD; Judy E. Kim, MD; Carl D. Regillo, MD, FACS|
|Source: Healio Ophthalmology Education Lab|
Provider: Vindico Medical Education
Number of Credits: 1.25
Although rapid advances have been made in the treatment of diabetic macular edema (DME), particularly with the use of intravitreal therapy, options for the management of diabetic retinopathy (DR) have remained limited. Until recently, the primary approach for the management of DR was the use of panretinal photocoagulation therapy. Additional treatment options for DR were discovered in view of analysis of data from studies of anti-vascular endothelial growth factor (VEGF) therapy for DME. The RISE and RIDE pivotal trials demonstrated large, rapid, and sustained improvements in eyes with DME when treated with ranibizumab. Since then, new information on the optimal management of diabetic retinal disease with anti-VEGF therapy has been obtained from subanalyses of these studies and their open-label extensions. Advances in knowledge of DR and its treatment have also been obtained from the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S trial, which is the first randomized, controlled trial to compare the anti-VEGF ranibizumab with laser therapy for the treatment of proliferative DR. This CME monograph will review the current evidence for the screening and assessment as well as the efficacy of treatments for DR.